Article |
By Dan Bowles, Mike Johnson, and Brian Swierenga,Cambrex
To meet ambitious orphan drug development timelines, CDMOs must be able to scale quickly to progress from early clinical development to validation and commercial launch.
More efficient development of drugs with attractive side effect profiles requires robust, easy-to-use, cost-effective in vitro gut models that are physiologically representative of the human intestinal tract.
In its commitment to the delivery of novel molecular formats, Lonza has designed a CMC strategy for bispecific molecules that enables delivery of a data package for IND submission within 13 months.
Sometimes your size exclusion chromatography (SEC) results don’t look like you want them to. Fix issues such as poor resolution, peak tailing, and fronting with the tips in this FAQ.
Infrastructure and expertise cover the sweet spot for producing the small-to-midsize batches needed to meet industry demands for PDFs and orphan drugs, and extend to large-scale manufacturing as well.
Lonza Pharma & Biotech’s Dr. Raphael Frey and Dr. Sandro Holzer answer attendee questions from a recent webinar about the challenges when moving a bioconjugate candidate from early development to clinic.
In a recent webinar, Giovanna Libralon, senior director of commercial development at Lonza, and Conrad Roten, group leader for API development services, shared insights into Lonza’s approach to integrated small molecule development.
